{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T03:25:53Z","timestamp":1782444353448,"version":"3.54.5"},"reference-count":216,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Microbiol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1038\/s41579-026-01295-x","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T11:39:24Z","timestamp":1773401964000},"page":"496-510","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Human herpesvirus evasion of humoral immunity and implications for vaccine development"],"prefix":"10.1038","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7127-2327","authenticated-orcid":false,"given":"Claire E.","family":"Otero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8288-787X","authenticated-orcid":false,"given":"Matthew D.","family":"Slein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1189-1873","authenticated-orcid":false,"given":"Libby","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3057-2362","authenticated-orcid":false,"given":"Adarsh","family":"Ramloul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7935-217X","authenticated-orcid":false,"given":"Philipp","family":"Kolb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4253-3476","authenticated-orcid":false,"given":"Margaret E.","family":"Ackerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1438-4554","authenticated-orcid":false,"given":"Sallie R.","family":"Permar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"key":"1295_CR1","doi-asserted-by":"crossref","unstructured":"Burrell, C. J., Howard, C. R. & Murphy, F. A. in Fenner and White\u2019s Medical Virology 5th edn (eds Burrell, C. J., Howard, C. R. & Murphy, F. A.) 237\u2013261 (Academic, 2017).","DOI":"10.1016\/B978-0-12-375156-0.00017-5"},{"key":"1295_CR2","doi-asserted-by":"publisher","first-page":"647992","DOI":"10.3389\/fcimb.2021.647992","volume":"11","author":"D Bhowmik","year":"2021","unstructured":"Bhowmik, D. & Zhu, F. Evasion of intracellular DNA sensing by human herpesviruses. Front. Cell. Infect. Microbiol.\u00a011, 647992 (2021).","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"1295_CR3","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41577-019-0225-5","volume":"20","author":"R Berry","year":"2020","unstructured":"Berry, R., Watson, G. M., Jonjic, S., Degli-Esposti, M. A. & Rossjohn, J. Modulation of innate and adaptive immunity by cytomegaloviruses. Nat. Rev. Immunol. 20, 113\u2013127 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"1295_CR4","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.vetmic.2010.02.017","volume":"143","author":"BD Griffin","year":"2010","unstructured":"Griffin, B. D., Verweij, M. C. & Wiertz, E. J. H. J. Herpesviruses and immunity: the art of evasion. Vet. Microbiol. 143, 89\u2013100 (2010).","journal-title":"Vet. Microbiol."},{"key":"1295_CR5","doi-asserted-by":"publisher","first-page":"167214","DOI":"10.1016\/j.jmb.2021.167214","volume":"434","author":"PT Lange","year":"2022","unstructured":"Lange, P. T., White, M. C. & Damania, B. Activation and evasion of innate immunity by gammaherpesviruses. J. Mol. Biol. 434, 167214 (2022).","journal-title":"J. Mol. Biol."},{"key":"1295_CR6","doi-asserted-by":"publisher","first-page":"1297994","DOI":"10.3389\/fimmu.2024.1297994","volume":"15","author":"JdM Silva","year":"2024","unstructured":"Silva, J.dM., Alves, C. E.dC. & Pontes, G. S. Epstein\u2013Barr virus: the mastermind of immune chaos. Front. Immunol.\u00a015, 1297994 (2024).","journal-title":"Front. Immunol."},{"key":"1295_CR7","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/cmi.2014.85","volume":"12","author":"P Lu\u010din","year":"2015","unstructured":"Lu\u010din, P., Mahmutefendi\u0107, H., Blagojevi\u0107 Zagorac, G. & Ili\u0107 Toma\u0161, M. Cytomegalovirus immune evasion by perturbation of endosomal trafficking. Cell. Mol. Immunol. 12, 154\u2013169 (2015).","journal-title":"Cell. Mol. Immunol."},{"key":"1295_CR8","doi-asserted-by":"publisher","first-page":"3361","DOI":"10.1172\/JCI136225","volume":"130","author":"JI Cohen","year":"2020","unstructured":"Cohen, J. I. Herpesvirus latency. J. Clin. Invest. 130, 3361\u20133369 (2020).","journal-title":"J. Clin. Invest."},{"key":"1295_CR9","doi-asserted-by":"publisher","first-page":"5705","DOI":"10.1016\/j.cell.2023.11.015","volume":"186","author":"H Vietzen","year":"2023","unstructured":"Vietzen, H. et al. Ineffective control of Epstein\u2013Barr-virus-induced autoimmunity increases the risk for multiple sclerosis. Cell 186, 5705\u20135718.e13 (2023).","journal-title":"Cell"},{"key":"1295_CR10","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.3390\/jcm11113061","volume":"11","author":"C Romanescu","year":"2022","unstructured":"Romanescu, C., Schreiner, T. G. & Mukovozov, I. The role of human herpesvirus 6 infection in Alzheimer\u2019s disease pathogenicity \u2014 a theoretical mosaic. J. Clin. Med. 11, 3061 (2022).","journal-title":"J. Clin. Med."},{"key":"1295_CR11","doi-asserted-by":"publisher","first-page":"966","DOI":"10.3390\/v11100966","volume":"11","author":"CA Mangold","year":"2019","unstructured":"Mangold, C. A. & Szpara, M. L. Persistent infection with herpes simplex virus 1 and Alzheimer\u2019s disease \u2014 a call to study how variability in both virus and host may impact disease. Viruses\u00a011, 966 (2019).","journal-title":"Viruses"},{"key":"1295_CR12","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1001\/jama.289.2.203","volume":"289","author":"ZA Brown","year":"2003","unstructured":"Brown, Z. A. et al. Effect of serologic status and cesarean delivery on transmission rates of herpes simplex virus from mother to infant. JAMA 289, 203\u2013209 (2003).","journal-title":"JAMA"},{"key":"1295_CR13","doi-asserted-by":"publisher","first-page":"1276912","DOI":"10.3389\/fped.2023.1276912","volume":"11","author":"S Salom\u00e8","year":"2023","unstructured":"Salom\u00e8, S. et al. Congenital cytomegalovirus infection: the state of the art and future perspectives. Front. Pediatr.\u00a011, 1276912 (2023).","journal-title":"Front. Pediatr."},{"key":"1295_CR14","first-page":"5","volume":"24","author":"RA Shah","year":"2019","unstructured":"Shah, R. A. et al. Shingrix for herpes zoster: a review. Skin Therapy Lett. 24, 5\u20137 (2019).","journal-title":"Skin Therapy Lett."},{"key":"1295_CR15","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/j.1529-8019.2009.01226.x","volume":"22","author":"R Creed","year":"2009","unstructured":"Creed, R., Satyaprakash, A. & Ravanfar, P. Varicella zoster vaccines. Dermatol. Ther. 22, 143\u2013149 (2009).","journal-title":"Dermatol. Ther."},{"key":"1295_CR16","doi-asserted-by":"publisher","first-page":"192","DOI":"10.3390\/v14020192","volume":"14","author":"A Patil","year":"2022","unstructured":"Patil, A., Goldust, M. & Wollina, U. Herpes zoster: a review of clinical manifestations and management. Viruses\u00a014, 192\u00a0(2022).","journal-title":"Viruses"},{"key":"1295_CR17","first-page":"95","volume":"41","author":"G Freer","year":"2018","unstructured":"Freer, G. & Pistello, M. Varicella-zoster virus infection: natural history, clinical manifestations, immunity and current and future vaccination strategies. New Microbiol. 41, 95\u2013105 (2018).","journal-title":"New Microbiol."},{"key":"1295_CR18","doi-asserted-by":"publisher","first-page":"e263","DOI":"10.1016\/S2666-7568(22)00039-3","volume":"3","author":"JF Mbinta","year":"2022","unstructured":"Mbinta, J. F., Nguyen, B. P., Awuni, P. M. A., Paynter, J. & Simpson, C. R. Post-licensure zoster vaccine effectiveness against herpes zoster and postherpetic neuralgia in older adults: a systematic review and meta-analysis. Lancet Healthy Longev. 3, e263\u2013e275 (2022).","journal-title":"Lancet Healthy Longev."},{"key":"1295_CR19","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1080\/14760584.2017.1343669","volume":"16","author":"P Wutzler","year":"2017","unstructured":"Wutzler, P. et al. Varicella vaccination \u2014 the global experience. Expert Rev. Vaccines 16, 833\u2013843 (2017).","journal-title":"Expert Rev. Vaccines"},{"key":"1295_CR20","doi-asserted-by":"publisher","first-page":"S425","DOI":"10.1093\/infdis\/jiac299","volume":"226","author":"ED Shapiro","year":"2022","unstructured":"Shapiro, E. D. & Marin, M. The effectiveness of varicella vaccine: 25\u2009years of postlicensure experience in the United States. J. Infect. Dis. 226, S425\u2013S430 (2022).","journal-title":"J. Infect. Dis."},{"key":"1295_CR21","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1016\/j.vaccine.2012.05.050","volume":"31","author":"GS Goldman","year":"2013","unstructured":"Goldman, G. S. & King, P. G. Review of the United States universal varicella vaccination program: herpes zoster incidence rates, cost-effectiveness, and vaccine efficacy based primarily on the antelope valley varicella active surveillance project data. Vaccine 31, 1680\u20131694 (2013).","journal-title":"Vaccine"},{"key":"1295_CR22","doi-asserted-by":"publisher","first-page":"1039537","DOI":"10.3389\/fpubh.2022.1039537","volume":"10","author":"M Shu","year":"2022","unstructured":"Shu, M., Zhang, D., Ma, R., Yang, T. & Pan, X. Long-term vaccine efficacy of a 2-dose varicella vaccine in China from 2011 to 2021: a retrospective observational study. Front. Public Health 10, 1039537 (2022).","journal-title":"Front. Public Health"},{"key":"1295_CR23","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1056\/NEJM199111283252204","volume":"325","author":"I Hardy","year":"1991","unstructured":"Hardy, I., Gershon, A. A., Steinberg, S. P., LaRussa, P. &\u00a0Varicella Vaccine Collaborative Study Group. The incidence of zoster after immunization with live attenuated varicella vaccine\u00a0\u2014 a study in children with leukemia.\u00a0N. Engl. J. Med. 325, 1545\u20131550 (1991).","journal-title":"N. Engl. J. Med."},{"key":"1295_CR24","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1093\/infdis\/jit405","volume":"208","author":"S Weinmann","year":"2013","unstructured":"Weinmann, S. et al. Incidence and clinical characteristics of herpes zoster among children in the varicella vaccine era, 2005\u20132009. J. Infect. Dis. 208, 1859\u20131868 (2013).","journal-title":"J. Infect. Dis."},{"key":"1295_CR25","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.coviro.2017.03.011","volume":"23","author":"AD Kosinska","year":"2017","unstructured":"Kosinska, A. D., Bauer, T. & Protzer, U. Therapeutic vaccination for chronic hepatitis B. Curr. Opin. Virol. 23, 75\u201381 (2017).","journal-title":"Curr. Opin. Virol."},{"key":"1295_CR26","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1177\/2051013616655980","volume":"4","author":"L Wang","year":"2016","unstructured":"Wang, L., Zhu, L. & Zhu, H. Efficacy of varicella (VZV) vaccination: an update for the clinician. Ther. Adv. Vaccines 4, 20\u201331 (2016).","journal-title":"Ther. Adv. Vaccines"},{"key":"1295_CR27","unstructured":"US Centers for Disease Control and Prevention. Shingles vaccination. CDC https:\/\/www.cdc.gov\/shingles\/vaccines\/index.html (2025)."},{"key":"1295_CR28","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","volume":"372","author":"H Lal","year":"2015","unstructured":"Lal, H. et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N. Engl. J. Med. 372, 2087\u20132096 (2015).","journal-title":"N. Engl. J. Med."},{"key":"1295_CR29","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1093\/infdis\/jis497","volume":"206","author":"I Leroux-Roels","year":"2012","unstructured":"Leroux-Roels, I. et al. A phase 1\/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein E subunit vaccine candidate in young and older adults. J. Infect. Dis. 206, 1280\u20131290 (2012).","journal-title":"J. Infect. Dis."},{"key":"1295_CR30","doi-asserted-by":"publisher","first-page":"6776","DOI":"10.1016\/j.vaccine.2019.09.031","volume":"37","author":"H Asada","year":"2019","unstructured":"Asada, H. VZV-specific cell-mediated immunity, but not humoral immunity, correlates inversely with the incidence of herpes zoster and the severity of skin symptoms and zoster-associated pain: the SHEZ study. Vaccine 37, 6776\u20136781 (2019).","journal-title":"Vaccine"},{"key":"1295_CR31","doi-asserted-by":"publisher","first-page":"S53","DOI":"10.1016\/j.vaccine.2023.06.020","volume":"41","author":"SB Boppana","year":"2023","unstructured":"Boppana, S. B. et al. Vaccine value profile for cytomegalovirus. Vaccine 41, S53\u2013S75 (2023).","journal-title":"Vaccine"},{"key":"1295_CR32","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05085366 (2025)."},{"key":"1295_CR33","unstructured":"ACCESS Newswire. Moderna provides business and pipeline updates at 43rd Annual J.P. Morgan Healthcare Conference. ACCESS Newswire https:\/\/www.accessnewswire.com\/newsroom\/en\/healthcare-and-pharmaceutical\/moderna-provides-business-and-pipeline-updates-at-43rd-annual-j.p.-mor-967378 (2025)."},{"key":"1295_CR34","unstructured":"ACCESS Newswire. Moderna announces phase 3 study of investigational cytomegalovirus (CMV) vaccine did not meet primary efficacy endpoint. ACCESS Newswire https:\/\/www.accessnewswire.com\/newsroom\/en\/healthcare-and-pharmaceutical\/moderna-announces-phase-3-study-of-investigational-cytomegalovirus-cm-1090841 (2025)."},{"key":"1295_CR35","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05683457 (2025)."},{"key":"1295_CR36","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05164094 (2025)."},{"key":"1295_CR37","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT06735248 (2025)."},{"key":"1295_CR38","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04645147 (2025)."},{"key":"1295_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39770-1","volume":"14","author":"V Dasari","year":"2023","unstructured":"Dasari, V. et al. Lymph node targeted multi-epitope subunit vaccine promotes effective immunity to EBV in HLA-expressing mice. Nat. Commun. 14, 4371 (2023).","journal-title":"Nat. Commun."},{"key":"1295_CR40","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s43556-024-00199-7","volume":"5","author":"L Bai","year":"2024","unstructured":"Bai, L., Xu, J., Zeng, L., Zhang, L. & Zhou, F. A review of HSV pathogenesis, vaccine development, and advanced applications. Mol. Biomed. 5, 35 (2024).","journal-title":"Mol. Biomed."},{"key":"1295_CR41","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/978-3-319-53168-7_9","volume":"223","author":"KW Jarosinski","year":"2017","unstructured":"Jarosinski, K. W. Interindividual spread of herpesviruses. Adv. Anat. Embryol. Cell Biol. 223, 195\u2013224 (2017).","journal-title":"Adv. Anat. Embryol. Cell Biol."},{"key":"1295_CR42","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/978-981-10-7230-7_19","volume":"1045","author":"S Fujiwara","year":"2018","unstructured":"Fujiwara, S. Animal models of human gammaherpesvirus infections. Adv. Exp. Med. Biol. 1045, 413\u2013436 (2018).","journal-title":"Adv. Exp. Med. Biol."},{"key":"1295_CR43","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s13365-014-0302-2","volume":"21","author":"CM Kollias","year":"2015","unstructured":"Kollias, C. M., Huneke, R. B., Wigdahl, B. & Jennings, S. R. Animal models of herpes simplex virus immunity and pathogenesis. J. Neurovirol. 21, 8\u201323 (2015).","journal-title":"J. Neurovirol."},{"issue":"Suppl 1","key":"1295_CR44","doi-asserted-by":"publisher","first-page":"S48","DOI":"10.1093\/infdis\/166.Supplement_1.S48","volume":"166","author":"MG Myers","year":"1992","unstructured":"Myers, M. G. & Connelly, B. L. Animal models of varicella. J. Infect. Dis. 166 (Suppl. 1), S48\u2013S50 (1992).","journal-title":"J. Infect. Dis."},{"key":"1295_CR45","doi-asserted-by":"publisher","first-page":"S60","DOI":"10.1093\/infdis\/jiz484","volume":"221","author":"HK Roark","year":"2020","unstructured":"Roark, H. K., Jenks, J. A., Permar, S. R. & Schleiss, M. R. Animal models of congenital cytomegalovirus transmission: implications for vaccine development. J. Infect. Dis. 221, S60\u2013S73 (2020).","journal-title":"J. Infect. Dis."},{"key":"1295_CR46","first-page":"149","volume":"232","author":"DC Johnson","year":"1998","unstructured":"Johnson, D. C. & Hill, A. B. Herpesvirus evasion of the immune system. Curr. Top. Microbiol. Immunol. 232, 149\u2013177 (1998).","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"1295_CR47","doi-asserted-by":"publisher","first-page":"7503","DOI":"10.3390\/ijms22147503","volume":"22","author":"DG Sausen","year":"2021","unstructured":"Sausen, D. G., Reed, K. M., Bhutta, M. S., Gallo, E. S. & Borenstein, R. Evasion of the host immune response by betaherpesviruses. Int. J. Mol. Sci.\u00a022, 7503\u00a0(2021).","journal-title":"Int. J. Mol. Sci."},{"key":"1295_CR48","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.3390\/v12121354","volume":"12","author":"N Koyanagi","year":"2020","unstructured":"Koyanagi, N. & Kawaguchi, Y. Evasion of the cell-mediated immune response by alphaherpesviruses. Viruses\u00a012, 1354\u00a0(2020).","journal-title":"Viruses"},{"key":"1295_CR49","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1089\/vim.2022.0200","volume":"36","author":"Y Yao","year":"2023","unstructured":"Yao, Y., Kong, W., Yang, L., Ding, Y. & Cui, H. Immunity and immune evasion mechanisms of Epstein\u2013Barr virus. Viral Immunol. 36, 303\u2013317 (2023).","journal-title":"Viral Immunol."},{"key":"1295_CR50","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1016\/j.immuni.2022.10.017","volume":"55","author":"I Wahl","year":"2022","unstructured":"Wahl, I. & Wardemann, H. Sterilizing immunity: understanding COVID-19. Immunity 55, 2231\u20132235 (2022).","journal-title":"Immunity"},{"key":"1295_CR51","doi-asserted-by":"crossref","unstructured":"Dunmire, S. K., Hogquist, K. A. & Balfour, H. H. in Epstein Barr Virus Volume 1 \u2014 One Herpes Virus: Many Diseases (ed. M\u00fcnz, C.) 211\u2013240 (Springer, 2015).","DOI":"10.1007\/978-3-319-22822-8_9"},{"key":"1295_CR52","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.1016\/j.antiviral.2004.06.004","volume":"63","author":"SL Sacks","year":"2004","unstructured":"Sacks, S. L. et al. HSV shedding. Antivir. Res. 63, S19\u2013S26 (2004).","journal-title":"Antivir. Res."},{"key":"1295_CR53","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.jogc.2021.07.013","volume":"44","author":"A Weber","year":"2022","unstructured":"Weber, A., Liu, M., Embree, J., Castillo, E. & Poliquin, V. Knowledge of congenital CMV, risk behaviours for CMV acquisition, and acceptance of an educational infographic among postpartum women: a pilot study. J. Obstet. Gynaecol. Can. 44, 200\u2013203 (2022).","journal-title":"J. Obstet. Gynaecol. Can."},{"key":"1295_CR54","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1038\/nm1213","volume":"11","author":"J Holmgren","year":"2005","unstructured":"Holmgren, J. & Czerkinsky, C. Mucosal immunity and vaccines. Nat. Med. 11, S45\u2013S53 (2005).","journal-title":"Nat. Med."},{"key":"1295_CR55","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s00430-019-00597-7","volume":"208","author":"AC M\u00e9ndez","year":"2019","unstructured":"M\u00e9ndez, A. C., Rodr\u00edguez-Rojas, C. & Del Val, M. Vaccine vectors: the bright side of cytomegalovirus. Med. Microbiol. Immunol. 208, 349\u2013363 (2019).","journal-title":"Med. Microbiol. Immunol."},{"key":"1295_CR56","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1128\/JVI.77.3.1840-1847.2003","volume":"77","author":"D Sitki-Green","year":"2003","unstructured":"Sitki-Green, D., Covington, M. & Raab-Traub, N. Compartmentalization and transmission of multiple Epstein\u2013Barr virus strains in asymptomatic carriers. J. Virol. 77, 1840\u20131847 (2003).","journal-title":"J. Virol."},{"key":"1295_CR57","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/imcb.12324","volume":"98","author":"BS Goldberg","year":"2020","unstructured":"Goldberg, B. S. & Ackerman, M. E. Antibody-mediated complement activation in pathology and protection. Immunol. Cell Biol. 98, 305\u2013317 (2020).","journal-title":"Immunol. Cell Biol."},{"key":"1295_CR58","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.3389\/fimmu.2019.02110","volume":"10","author":"JA Jenks","year":"2019","unstructured":"Jenks, J. A., Goodwin, M. L. & Permar, S. R. The roles of host and viral antibody fc receptors in herpes simplex virus (HSV) and human cytomegalovirus (HCMV) infections and immunity. Front. Immunol. 10, 2110 (2019).","journal-title":"Front. Immunol."},{"key":"1295_CR59","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1011670","volume":"19","author":"TL Chandler","year":"2023","unstructured":"Chandler, T. L., Yang, A., Otero, C. E., Permar, S. R. & Caddy, S. L. Protective mechanisms of nonneutralizing antiviral antibodies. PLoS Pathog. 19, e1011670 (2023).","journal-title":"PLoS Pathog."},{"key":"1295_CR60","doi-asserted-by":"publisher","first-page":"100925","DOI":"10.1016\/j.medj.2025.100925","volume":"7","author":"V Roy","year":"2026","unstructured":"Roy, V. et al. Epstein\u2013Barr-virus-specific functional antibody signatures in the context of nasopharyngeal carcinoma development. Med 7, 100925 (2026).","journal-title":"Med"},{"key":"1295_CR61","doi-asserted-by":"publisher","DOI":"10.1172\/JCI156827","volume":"132","author":"EC Semmes","year":"2022","unstructured":"Semmes, E. C. et al. Maternal Fc-mediated non-neutralizing antibody responses correlate with protection against congenital human cytomegalovirus infection. J. Clin. Invest.\u00a0132, e156827 (2022).","journal-title":"J. Clin. Invest."},{"key":"1295_CR62","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.167768","volume":"8","author":"EC Semmes","year":"2023","unstructured":"Semmes, E. C. et al. ADCC-activating antibodies correlate with decreased risk of congenital human cytomegalovirus transmission. JCI Insight\u00a08, e167768 (2023).","journal-title":"JCI Insight"},{"key":"1295_CR63","doi-asserted-by":"publisher","first-page":"959603","DOI":"10.3389\/fimmu.2022.959603","volume":"13","author":"IM Backes","year":"2022","unstructured":"Backes, I. M., Leib, D. A. & Ackerman, M. E. Monoclonal antibody therapy of herpes simplex virus: an opportunity to decrease congenital and perinatal infections. Front. Immunol. 13, 959603 (2022).","journal-title":"Front. Immunol."},{"key":"1295_CR64","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1093\/infdis\/160.5.770","volume":"160","author":"S Kohl","year":"1989","unstructured":"Kohl, S. et al. Neonatal antibody-dependent cellular cytotoxic antibody levels are associated with the clinical presentation of neonatal herpes simplex virus infection. J. Infect. Dis. 160, 770\u2013776 (1989).","journal-title":"J. Infect. Dis."},{"key":"1295_CR65","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1084\/jem.179.5.1713","volume":"179","author":"S Jonji\u0107","year":"1994","unstructured":"Jonji\u0107, S. et al. Antibodies are not essential for the resolution of primary cytomegalovirus infection but limit dissemination of recurrent virus. J. Exp. Med. 179, 1713\u20131717 (1994).","journal-title":"J. Exp. Med."},{"key":"1295_CR66","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1084\/jem.188.6.1047","volume":"188","author":"B Poli\u0107","year":"1998","unstructured":"Poli\u0107, B. et al. Hierarchical and redundant lymphocyte subset control precludes cytomegalovirus replication during latent infection. J. Exp. Med. 188, 1047\u20131054 (1998).","journal-title":"J. Exp. Med."},{"key":"1295_CR67","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s00430-008-0095-0","volume":"197","author":"N Wirtz","year":"2008","unstructured":"Wirtz, N. et al. Polyclonal cytomegalovirus-specific antibodies not only prevent virus dissemination from the portal of entry but also inhibit focal virus spread within target tissues. Med. Microbiol. Immunol. 197, 151\u2013158 (2008).","journal-title":"Med. Microbiol. Immunol."},{"key":"1295_CR68","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1182\/blood-2007-06-095414","volume":"110","author":"K Klenovsek","year":"2007","unstructured":"Klenovsek, K. et al. Protection from CMV infection in immunodeficient hosts by adoptive transfer of memory B cells. Blood 110, 3472\u20133479 (2007).","journal-title":"Blood"},{"key":"1295_CR69","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.94002","volume":"2","author":"CS Nelson","year":"2017","unstructured":"Nelson, C. S. et al. Preexisting antibodies can protect against congenital cytomegalovirus infection in monkeys. JCI Insight\u00a02, e94002 (2017).","journal-title":"JCI Insight"},{"key":"1295_CR70","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1056\/NEJMoa1913569","volume":"385","author":"BL Hughes","year":"2021","unstructured":"Hughes, B. L. et al. A trial of hyperimmune globulin to prevent congenital cytomegalovirus infection. N. Engl. J. Med. 385, 436\u2013444 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1295_CR71","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1097\/01.tp.0000202724.07714.a2","volume":"81","author":"A Humar","year":"2006","unstructured":"Humar, A. et al. A randomized trial of ganciclovir versus ganciclovir plus immune globulin for prophylaxis against Epstein\u2013Barr virus related posttransplant lymphoproliferative disorder. Transplantation 81, 856\u2013861 (2006).","journal-title":"Transplantation"},{"key":"1295_CR72","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.virol.2021.06.006","volume":"561","author":"J Kim","year":"2021","unstructured":"Kim, J. et al. Epstein\u2013Barr virus (EBV) hyperimmune globulin isolated from donors with high gp350 antibody titers protect humanized mice from challenge with EBV. Virology 561, 80\u201386 (2021).","journal-title":"Virology"},{"key":"1295_CR73","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1084\/jem.20030091","volume":"199","author":"BJ Hebeis","year":"2004","unstructured":"Hebeis, B. J. et al. Activation of virus-specific memory B cells in the absence of T cell help. J. Exp. Med. 199, 593\u2013602 (2004).","journal-title":"J. Exp. Med."},{"key":"1295_CR74","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/bs.aivir.2020.09.002","volume":"108","author":"N Cifuentes-Munoz","year":"2020","unstructured":"Cifuentes-Munoz, N., El Najjar, F. & Dutch, R. E. Viral cell-to-cell spread: conventional and non-conventional ways. Adv. Virus Res. 108, 85\u2013125 (2020).","journal-title":"Adv. Virus Res."},{"key":"1295_CR75","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/s41579-020-00448-w","volume":"19","author":"SA Connolly","year":"2021","unstructured":"Connolly, S. A., Jardetzky, T. S. & Longnecker, R. The structural basis of herpesvirus entry. Nat. Rev. Microbiol. 19, 110\u2013121 (2021).","journal-title":"Nat. Rev. Microbiol."},{"key":"1295_CR76","doi-asserted-by":"publisher","first-page":"9644","DOI":"10.3390\/ijms21249644","volume":"21","author":"H Leroy","year":"2020","unstructured":"Leroy, H. et al. Virus-mediated cell\u2013cell fusion. Int. J. Mol. Sci.\u00a021, 9644 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"1295_CR77","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1002\/rmv.377","volume":"13","author":"NL Cole","year":"2003","unstructured":"Cole, N. L. & Grose, C. Membrane fusion mediated by herpesvirus glycoproteins: the paradigm of varicella-zoster virus. Rev. Med. Virol. 13, 207\u2013222 (2003).","journal-title":"Rev. Med. Virol."},{"key":"1295_CR78","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.virol.2019.08.014","volume":"537","author":"E Feutz","year":"2019","unstructured":"Feutz, E., McLeland-Wieser, H., Ma, J. & Roller, R. J. Functional interactions between herpes simplex virus pUL51, pUL7 and gE reveal cell-specific mechanisms for epithelial cell-to-cell spread. Virology 537, 84\u201396 (2019).","journal-title":"Virology"},{"key":"1295_CR79","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/0042-6822(84)90022-9","volume":"137","author":"DJ Bzik","year":"1984","unstructured":"Bzik, D. J., Fox, B. A., DeLuca, N. A. & Person, S. Nucleotide sequence of a region of the herpes simplex virus type 1 gB glycoprotein gene: mutations affecting rate of virus entry and cell fusion. Virology 137, 185\u2013190 (1984).","journal-title":"Virology"},{"key":"1295_CR80","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1128\/jvi.35.1.105-113.1980","volume":"35","author":"GS Read","year":"1980","unstructured":"Read, G. S., Person, S. & Keller, P. M. Genetic studies of cell fusion induced by herpes simplex virus type 1. J. Virol. 35, 105\u2013113 (1980).","journal-title":"J. Virol."},{"key":"1295_CR81","doi-asserted-by":"publisher","first-page":"5629","DOI":"10.1128\/JVI.74.12.5629-5638.2000","volume":"74","author":"G Gerna","year":"2000","unstructured":"Gerna, G. et al. Human cytomegalovirus replicates abortively in polymorphonuclear leukocytes after transfer from infected endothelial cells via transient microfusion events. J. Virol. 74, 5629\u20135638 (2000).","journal-title":"J. Virol."},{"key":"1295_CR82","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1128\/JVI.72.1.873-875.1998","volume":"72","author":"A Turner","year":"1998","unstructured":"Turner, A., Bruun, B., Minson, T. & Browne, H. Glycoproteins gB, gD, and gHgL of herpes simplex virus type 1 are necessary and sufficient to mediate membrane fusion in a Cos cell transfection system. J. Virol. 72, 873\u2013875 (1998).","journal-title":"J. Virol."},{"key":"1295_CR83","doi-asserted-by":"publisher","first-page":"6836","DOI":"10.1128\/JVI.77.12.6836-6844.2003","volume":"77","author":"E Avitabile","year":"2003","unstructured":"Avitabile, E., Lombardi, G. & Campadelli-Fiume, G. Herpes simplex virus glycoprotein K, but not its syncytial allele, inhibits cell\u2013cell fusion mediated by the four fusogenic glycoproteins, gD, gB, gH, and gL. J. Virol. 77, 6836\u20136844 (2003).","journal-title":"J. Virol."},{"key":"1295_CR84","doi-asserted-by":"publisher","first-page":"1143870","DOI":"10.3389\/fimmu.2023.1143870","volume":"14","author":"M Alt","year":"2023","unstructured":"Alt, M. et al. Cell-to-cell spread inhibiting antibodies constitute a correlate of protection against herpes simplex virus type 1 reactivations: a retrospective study. Front. Immunol. 14, 1143870 (2023).","journal-title":"Front. Immunol."},{"key":"1295_CR85","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1007095","volume":"14","author":"LM Hook","year":"2018","unstructured":"Hook, L. M. et al. Vaccine-induced antibodies to herpes simplex virus glycoprotein D epitopes involved in virus entry and cell-to-cell spread correlate with protection against genital disease in guinea pigs. PLoS Pathog. 14, e1007095 (2018).","journal-title":"PLoS Pathog."},{"key":"1295_CR86","doi-asserted-by":"publisher","first-page":"e00070","DOI":"10.1128\/JVI.00070-19","volume":"93","author":"E Criscuolo","year":"2019","unstructured":"Criscuolo, E. et al. Cell-to-cell spread blocking activity is extremely limited in the sera of herpes simplex virus 1 (HSV-1)- and HSV-2-infected subjects. J. Virol.\u00a093, e00070-19 (2019).","journal-title":"J. Virol."},{"key":"1295_CR87","doi-asserted-by":"publisher","first-page":"e01650","DOI":"10.1128\/JVI.01650-16","volume":"91","author":"X Cui","year":"2017","unstructured":"Cui, X. et al. Impact of antibodies and strain polymorphisms on cytomegalovirus entry and spread in fibroblasts and epithelial cells. J. Virol.\u00a091, e01650-16 (2017).","journal-title":"J. Virol."},{"key":"1295_CR88","doi-asserted-by":"publisher","first-page":"500","DOI":"10.3390\/v10090500","volume":"10","author":"JJ Falk","year":"2018","unstructured":"Falk, J. J. et al. Large-scale screening of HCMV-seropositive blood donors indicates that HCMV effectively escapes from antibodies by cell-associated spread. Viruses 10, 500 (2018).","journal-title":"Viruses"},{"key":"1295_CR89","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1056\/NEJMoa1310214","volume":"370","author":"MG Revello","year":"2014","unstructured":"Revello, M. G. et al. A randomized trial of hyperimmune globulin to prevent congenital cytomegalovirus. N. Engl. J. Med. 370, 1316\u20131326 (2014).","journal-title":"N. Engl. J. Med."},{"key":"1295_CR90","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1002\/uog.19164","volume":"53","author":"KO Kagan","year":"2019","unstructured":"Kagan, K. O. et al. Prevention\u2009of\u2009maternal-fetal\u2009transmission\u2009of cytomegalovirus after primary maternal infection in the first trimester by biweekly hyperimmunoglobulin administration. Ultrasound Obstet. Gynecol. 53, 383\u2013389 (2019).","journal-title":"Ultrasound Obstet. Gynecol."},{"key":"1295_CR91","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.06054","volume":"4","author":"C Petro","year":"2015","unstructured":"Petro, C. et al. Herpes simplex type 2 virus deleted in glycoprotein D protects against vaginal, skin and neural disease. eLife\u00a04, e06054 (2015).","journal-title":"eLife"},{"key":"1295_CR92","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1016\/j.immuni.2019.03.010","volume":"50","author":"W Bu","year":"2019","unstructured":"Bu, W. et al. Immunization with components of the viral fusion apparatus elicits antibodies that neutralize Epstein\u2013Barr virus in B cells and epithelial cells. Immunity 50, 1305\u20131316.e6 (2019).","journal-title":"Immunity"},{"key":"1295_CR93","doi-asserted-by":"publisher","first-page":"e00143","DOI":"10.1128\/mBio.00143-21","volume":"12","author":"AT Hilterbrand","year":"2021","unstructured":"Hilterbrand, A. T., Daly, R. E. & Heldwein, E. E. Contributions of the four essential entry glycoproteins to HSV-1 tropism and the selection of entry routes. mBio\u00a012, e00143-21 (2021).","journal-title":"mBio"},{"key":"1295_CR94","doi-asserted-by":"publisher","first-page":"12612","DOI":"10.1128\/JVI.01930-14","volume":"88","author":"TM Cairns","year":"2014","unstructured":"Cairns, T. M. et al. Dissection of the antibody response against herpes simplex virus glycoproteins in naturally infected humans. J. Virol. 88, 12612\u201312622 (2014).","journal-title":"J. Virol."},{"key":"1295_CR95","doi-asserted-by":"publisher","first-page":"469","DOI":"10.21775\/cimb.041.469","volume":"41","author":"CB Aschner","year":"2021","unstructured":"Aschner, C. B. & Herold, B. C. Alphaherpesvirus vaccines. Curr. Issues Mol. Biol. 41, 469\u2013508 (2021).","journal-title":"Curr. Issues Mol. Biol."},{"key":"1295_CR96","doi-asserted-by":"publisher","first-page":"eaax2454","DOI":"10.1126\/sciimmunol.aax2454","volume":"5","author":"C Burn Aschner","year":"2020","unstructured":"Burn Aschner, C. et al. HVEM signaling promotes protective antibody-dependent cellular cytotoxicity (ADCC) vaccine responses to herpes simplex viruses. Sci. Immunol.\u00a05, eaax2454 (2020).","journal-title":"Sci. Immunol."},{"key":"1295_CR97","doi-asserted-by":"publisher","first-page":"e00335","DOI":"10.1128\/JVI.00335-20","volume":"94","author":"NLM Ramsey","year":"2020","unstructured":"Ramsey, N. L. M. et al. A single-cycle glycoprotein D deletion viral vaccine candidate, \u0394gD-2, elicits polyfunctional antibodies that protect against ocular herpes simplex virus. J. Virol.\u00a094, e00335-20 (2020).","journal-title":"J. Virol."},{"key":"1295_CR98","doi-asserted-by":"publisher","DOI":"10.1172\/JCI161968","volume":"133","author":"M Kuraoka","year":"2023","unstructured":"Kuraoka, M. et al. A non-neutralizing glycoprotein B monoclonal antibody protects against herpes simplex virus disease in mice. J. Clin. Invest. 133, e161968\u00a0(2023).","journal-title":"J. Clin. Invest."},{"key":"1295_CR99","doi-asserted-by":"publisher","first-page":"e01852","DOI":"10.1128\/JVI.01852-19","volume":"94","author":"T Komala Sari","year":"2020","unstructured":"Komala Sari, T., Gianopulos, K. A. & Nicola, A. V. Glycoprotein C of herpes simplex virus 1 shields glycoprotein B from antibody neutralization. J. Virol. 94, e01852-19\u00a0(2020).","journal-title":"J. Virol."},{"key":"1295_CR100","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002387","volume":"7","author":"B Machiels","year":"2011","unstructured":"Machiels, B. et al. Antibody evasion by a gammaherpesvirus O-glycan shield. PLoS Pathog. 7, e1002387 (2011).","journal-title":"PLoS Pathog."},{"key":"1295_CR101","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0176160","volume":"12","author":"XJ Jiang","year":"2017","unstructured":"Jiang, X. J. et al. Human cytomegalovirus glycoprotein polymorphisms and increasing viral load in AIDS patients. PLoS ONE\u00a012, e0176160 (2017).","journal-title":"PLoS ONE"},{"key":"1295_CR102","doi-asserted-by":"publisher","first-page":"e02051","DOI":"10.1128\/JVI.02051-19","volume":"94","author":"LZ Day","year":"2020","unstructured":"Day, L. Z. et al. Polymorphisms in human cytomegalovirus glycoprotein O (gO) exert epistatic influences on cell-free and cell-to-cell spread and antibody neutralization on gH epitopes. J. Virol. 94, e02051-19\u00a0(2020).","journal-title":"J. Virol."},{"key":"1295_CR103","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/nrd3012","volume":"9","author":"RD Astronomo","year":"2010","unstructured":"Astronomo, R. D. & Burton, D. R. Carbohydrate vaccines: developing sweet solutions to sticky situations? Nat. Rev. Drug Discov. 9, 308\u2013324 (2010).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1295_CR104","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.4049\/jimmunol.157.6.2229","volume":"157","author":"CM Snapper","year":"1996","unstructured":"Snapper, C. M. & Mond, J. J. A model for induction of T cell-independent humoral immunity in response to polysaccharide antigens. J. Immunol. 157, 2229\u20132233 (1996).","journal-title":"J. Immunol."},{"key":"1295_CR105","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.tim.2007.03.003","volume":"15","author":"DJ Vigerust","year":"2007","unstructured":"Vigerust, D. J. & Shepherd, V. L. Virus glycosylation: role in virulence and immune interactions. Trends Microbiol. 15, 211\u2013218 (2007).","journal-title":"Trends Microbiol."},{"key":"1295_CR106","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.tim.2022.02.004","volume":"30","author":"LP Deimel","year":"2022","unstructured":"Deimel, L. P., Xue, X. & Sattentau, Q. J. Glycans in HIV-1 vaccine design \u2014 engaging the shield. Trends Microbiol. 30, 866\u2013881 (2022).","journal-title":"Trends Microbiol."},{"key":"1295_CR107","volume":"14","author":"A Fukui","year":"2023","unstructured":"Fukui, A. et al. Dual impacts of a glycan shield on the envelope glycoprotein B of HSV-1: evasion from human antibodies in vivo and neurovirulence. mBio 14, e009923 (2023).","journal-title":"mBio"},{"key":"1295_CR108","doi-asserted-by":"publisher","first-page":"2966","DOI":"10.1038\/s41564-025-02153-x","volume":"10","author":"RS Roark","year":"2025","unstructured":"Roark, R. S. et al. Prefusion structure, evasion and neutralization of HSV-1 glycoprotein B. Nat. Microbiol. 10, 2966\u20132980 (2025).","journal-title":"Nat. Microbiol."},{"key":"1295_CR109","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/nature01470","volume":"422","author":"X Wei","year":"2003","unstructured":"Wei, X. et al. Antibody neutralization and escape by HIV-1. Nature 422, 307\u2013312 (2003).","journal-title":"Nature"},{"key":"1295_CR110","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00749-0","volume":"8","author":"SM Valencia","year":"2023","unstructured":"Valencia, S. M. et al. Vaccination with a replication-defective cytomegalovirus vaccine elicits a glycoprotein B-specific monoclonal antibody repertoire distinct from natural infection. npj Vaccines 8, 154 (2023).","journal-title":"npj Vaccines"},{"key":"1295_CR111","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1128\/MMBR.00018-16","volume":"80","author":"TJ Gardner","year":"2016","unstructured":"Gardner, T. J. & Tortorella, D. Virion glycoprotein-mediated immune evasion by human cytomegalovirus: a sticky virus makes a slick getaway. Microbiol. Mol. Biol. Rev. 80, 663\u2013677 (2016).","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"1295_CR112","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002999","volume":"8","author":"B Kropff","year":"2012","unstructured":"Kropff, B. et al. Glycoprotein N of human cytomegalovirus protects the virus from neutralizing antibodies. PLoS Pathog. 8, e1002999 (2012).","journal-title":"PLoS Pathog."},{"key":"1295_CR113","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005227","volume":"11","author":"HG Burke","year":"2015","unstructured":"Burke, H. G. & Heldwein, E. E. Crystal structure of the human cytomegalovirus glycoprotein B. PLoS Pathog. 11, e1005227 (2015).","journal-title":"PLoS Pathog."},{"key":"1295_CR114","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00090-25","volume":"99","author":"MA Hull","year":"2025","unstructured":"Hull, M. A., Pritchard, S. M. & Nicola, A. V. Herpes simplex virus 1 envelope glycoprotein C shields glycoprotein D to protect virions from entry-blocking antibodies. J. Virol. 99, e0009025 (2025).","journal-title":"J. Virol."},{"key":"1295_CR115","doi-asserted-by":"publisher","first-page":"5184","DOI":"10.1128\/jvi.63.12.5184-5193.1989","volume":"63","author":"DL Sodora","year":"1989","unstructured":"Sodora, D. L., Cohen, G. H. & Eisenberg, R. J. Influence of asparagine-linked oligosaccharides on antigenicity, processing, and cell surface expression of herpes simplex virus type 1 glycoprotein D. J. Virol. 63, 5184\u20135193 (1989).","journal-title":"J. Virol."},{"key":"1295_CR116","first-page":"333","volume":"325","author":"C Powers","year":"2008","unstructured":"Powers, C., DeFilippis, V., Malouli, D. & Fr\u00fch, K. Cytomegalovirus immune evasion. Curr. Top. Microbiol. Immunol. 325, 333\u2013359 (2008).","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"1295_CR117","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1089\/jir.2011.0083","volume":"32","author":"SH Sin","year":"2012","unstructured":"Sin, S. H. & Dittmer, D. P. Cytokine homologs of human gammaherpesviruses. J. Interferon Cytokine Res. 32, 53\u201359 (2012).","journal-title":"J. Interferon Cytokine Res."},{"key":"1295_CR118","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.3390\/v4112448","volume":"4","author":"BP McSharry","year":"2012","unstructured":"McSharry, B. P., Avdic, S. & Slobedman, B. Human cytomegalovirus encoded homologs of cytokines, chemokines and their receptors: roles in immunomodulation. Viruses 4, 2448\u20132470 (2012).","journal-title":"Viruses"},{"key":"1295_CR119","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1073\/pnas.97.4.1695","volume":"97","author":"SV Kotenko","year":"2000","unstructured":"Kotenko, S. V., Saccani, S., Izotova, L. S., Mirochnitchenko, O. V. & Pestka, S. Human cytomegalovirus harbors its own unique IL-10 homolog (cmvIL-10). Proc. Natl Acad. Sci. USA 97, 1695\u20131700 (2000).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1295_CR120","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.virol.2007.11.031","volume":"374","author":"JV Spencer","year":"2008","unstructured":"Spencer, J. V., Cadaoas, J., Castillo, P. R., Saini, V. & Slobedman, B. Stimulation of B lymphocytes by cmvIL-10 but not LAcmvIL-10. Virology 374, 164\u2013169 (2008).","journal-title":"Virology"},{"key":"1295_CR121","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1128\/JVI.76.3.1285-1292.2002","volume":"76","author":"JV Spencer","year":"2002","unstructured":"Spencer, J. V. et al. Potent immunosuppressive activities of cytomegalovirus-encoded interleukin-10. J. Virol. 76, 1285\u20131292 (2002).","journal-title":"J. Virol."},{"key":"1295_CR122","doi-asserted-by":"publisher","first-page":"8720","DOI":"10.1128\/JVI.78.16.8720-8731.2004","volume":"78","author":"WL Chang","year":"2004","unstructured":"Chang, W. L., Baumgarth, N., Yu, D. & Barry, P. A. Human cytomegalovirus-encoded interleukin-10 homolog inhibits maturation of dendritic cells and alters their functionality. J. Virol. 78, 8720\u20138731 (2004).","journal-title":"J. Virol."},{"key":"1295_CR123","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.4049\/jimmunol.173.5.3383","volume":"173","author":"MJ Raftery","year":"2004","unstructured":"Raftery, M. J. et al. Shaping phenotype, function, and survival of dendritic cells by cytomegalovirus-encoded IL-10. J. Immunol. 173, 3383\u20133391 (2004).","journal-title":"J. Immunol."},{"key":"1295_CR124","doi-asserted-by":"publisher","first-page":"9618","DOI":"10.1128\/JVI.01098-09","volume":"83","author":"B Slobedman","year":"2009","unstructured":"Slobedman, B., Barry, P. A., Spencer, J. V., Avdic, S. & Abendroth, A. Virus-encoded homologs of cellular interleukin-10 and their control of host immune function. J. Virol. 83, 9618\u20139629 (2009).","journal-title":"J. Virol."},{"key":"1295_CR125","doi-asserted-by":"publisher","first-page":"3084","DOI":"10.3389\/fimmu.2019.03084","volume":"10","author":"G Broussard","year":"2020","unstructured":"Broussard, G. & Damania, B. KSHV: immune modulation and immunotherapy. Front. Immunol. 10, 3084\u00a0(2020).","journal-title":"Front. Immunol."},{"key":"1295_CR126","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41421-024-00684-x","volume":"10","author":"Y Chen","year":"2024","unstructured":"Chen, Y. et al. A homotrimeric GPCR architecture of the human cytomegalovirus revealed by cryo-EM. Cell Discov. 10, 52 (2024).","journal-title":"Cell Discov."},{"key":"1295_CR127","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1128\/JVI.79.1.536-546.2005","volume":"79","author":"SJ Paulsen","year":"2005","unstructured":"Paulsen, S. J., Rosenkilde, M. M., Eugen-Olsen, J. & Kledal, T. N. Epstein\u2013Barr virus-encoded BILF1 is a constitutively active G protein-coupled receptor. J. Virol. 79, 536\u2013546 (2005).","journal-title":"J. Virol."},{"key":"1295_CR128","doi-asserted-by":"publisher","first-page":"16642","DOI":"10.1073\/pnas.0407233101","volume":"101","author":"D Wang","year":"2004","unstructured":"Wang, D., Bresnahan, W. & Shenk, T. Human cytomegalovirus encodes a highly specific RANTES decoy receptor. Proc. Natl Acad. Sci. USA 101, 16642\u201316647 (2004).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1295_CR129","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1126\/science.288.5475.2373","volume":"288","author":"WA Bresnahan","year":"2000","unstructured":"Bresnahan, W. A. & Shenk, T. A subset of viral transcripts packaged within human cytomegalovirus particles. Science 288, 2373\u20132376 (2000).","journal-title":"Science"},{"key":"1295_CR130","doi-asserted-by":"publisher","first-page":"548","DOI":"10.2174\/187152609789105696","volume":"9","author":"J Vomaske","year":"2009","unstructured":"Vomaske, J., Nelson, J. A. & Streblow, D. N. Human cytomegalovirus US28: a functionally selective chemokine binding receptor. Infect. Disord. Drug Targets 9, 548\u2013556 (2009).","journal-title":"Infect. Disord. Drug Targets"},{"key":"1295_CR131","doi-asserted-by":"publisher","first-page":"8108","DOI":"10.1128\/JVI.77.14.8108-8115.2003","volume":"77","author":"K Nakano","year":"2003","unstructured":"Nakano, K. et al. Human herpesvirus 7 open reading frame U12 encodes a functional \u03b2-chemokine receptor. J. Virol. 77, 8108\u20138115 (2003).","journal-title":"J. Virol."},{"key":"1295_CR132","doi-asserted-by":"publisher","first-page":"6104","DOI":"10.1128\/JVI.72.7.6104-6112.1998","volume":"72","author":"Y Isegawa","year":"1998","unstructured":"Isegawa, Y., Ping, Z., Nakano, K., Sugimoto, N. & Yamanishi, K. Human herpesvirus 6 open reading frame U12 encodes a functional \u03b2-chemokine receptor. J. Virol. 72, 6104\u20136112 (1998).","journal-title":"J. Virol."},{"key":"1295_CR133","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1128\/jcm.2.4.332-336.1975","volume":"2","author":"T Furukawa","year":"1975","unstructured":"Furukawa, T., Hornberger, E., Sakuma, S. & Plotkin, S. A. Demonstration of immunoglobulin G receptors induced by human cytomegalovirus. J. Clin. Microbiol. 2, 332\u2013336 (1975).","journal-title":"J. Clin. Microbiol."},{"key":"1295_CR134","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1128\/jvi.32.3.779-789.1979","volume":"32","author":"RB Baucke","year":"1979","unstructured":"Baucke, R. B. & Spear, P. G. Membrane proteins specified by herpes simplex viruses. V. Identification of an Fc-binding glycoprotein. J. Virol. 32, 779\u2013789 (1979).","journal-title":"J. Virol."},{"key":"1295_CR135","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1128\/iai.26.2.770-774.1979","volume":"26","author":"M Ogata","year":"1979","unstructured":"Ogata, M. & Shigeta, S. Appearance of immunoglobulin G Fc receptor in cultured human cells infected with varicella-zoster virus. Infect. Immun. 26, 770\u2013774 (1979).","journal-title":"Infect. Immun."},{"key":"1295_CR136","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1086\/514255","volume":"178","author":"JK Olson","year":"1998","unstructured":"Olson, J. K., Santos, R. A. & Grose, C. Varicella-zoster virus glycoprotein gE: endocytosis and trafficking of the Fc receptor. J. Infect. Dis. 178, S2\u2013S6 (1998).","journal-title":"J. Infect. Dis."},{"key":"1295_CR137","doi-asserted-by":"publisher","first-page":"7046","DOI":"10.1128\/jvi.65.12.7046-7050.1991","volume":"65","author":"G Dubin","year":"1991","unstructured":"Dubin, G., Socolof, E., Frank, I. & Friedman, H. M. Herpes simplex virus type 1 Fc receptor protects infected cells from antibody-dependent cellular cytotoxicity. J. Virol. 65, 7046\u20137050 (1991).","journal-title":"J. Virol."},{"key":"1295_CR138","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1128\/jvi.71.1.110-119.1997","volume":"71","author":"JK Olson","year":"1997","unstructured":"Olson, J. K., Bishop, G. A. & Grose, C. Varicella-zoster virus Fc receptor gE glycoprotein: serine\/threonine and tyrosine phosphorylation of monomeric and dimeric forms. J. Virol. 71, 110\u2013119 (1997).","journal-title":"J. Virol."},{"key":"1295_CR139","doi-asserted-by":"publisher","first-page":"8933","DOI":"10.1128\/JVI.72.11.8933-8942.1998","volume":"72","author":"KS Dingwell","year":"1998","unstructured":"Dingwell, K. S. & Johnson, D. C. The herpes simplex virus gE\u2013gI complex facilitates cell-to-cell spread and binds to components of cell junctions. J. Virol. 72, 8933\u20138942 (1998).","journal-title":"J. Virol."},{"key":"1295_CR140","doi-asserted-by":"publisher","first-page":"7087","DOI":"10.1128\/jvi.69.11.7087-7098.1995","volume":"69","author":"KS Dingwell","year":"1995","unstructured":"Dingwell, K. S., Doering, L. C. & Johnson, D. C. Glycoproteins E and I facilitate neuron-to-neuron spread of herpes simplex virus. J. Virol. 69, 7087\u20137098 (1995).","journal-title":"J. Virol."},{"key":"1295_CR141","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.1128\/JVI.02509-10","volume":"85","author":"JM Lubinski","year":"2011","unstructured":"Lubinski, J. M., Lazear, H. M., Awasthi, S., Wang, F. & Friedman, H. M. The herpes simplex virus 1 IgG fc receptor blocks antibody-mediated complement activation and antibody-dependent cellular cytotoxicity in vivo. J. Virol. 85, 3239\u20133249 (2011).","journal-title":"J. Virol."},{"key":"1295_CR142","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1038\/2021364a0","volume":"202","author":"JF Watkins","year":"1964","unstructured":"Watkins, J. F. Adsorption of sensitized sheep erythrocytes to HeLa cells infected with herpes simplex virus. Nature 202, 1364\u20131365 (1964).","journal-title":"Nature"},{"key":"1295_CR143","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1128\/jvi.62.4.1347-1354.1988","volume":"62","author":"DC Johnson","year":"1988","unstructured":"Johnson, D. C., Frame, M. C., Ligas, M. W., Cross, A. M. & Stow, N. D. Herpes simplex virus immunoglobulin G Fc receptor activity depends on a complex of two viral glycoproteins, gE and gI. J. Virol. 62, 1347\u20131354 (1988).","journal-title":"J. Virol."},{"key":"1295_CR144","doi-asserted-by":"publisher","first-page":"6911","DOI":"10.1074\/jbc.274.11.6911","volume":"274","author":"TL Chapman","year":"1999","unstructured":"Chapman, T. L. et al. Characterization of the interaction between the herpes simplex virus type I Fc receptor and immunoglobulin G. J. Biol. Chem. 274, 6911\u20136919 (1999).","journal-title":"J. Biol. Chem."},{"key":"1295_CR145","doi-asserted-by":"publisher","first-page":"2725","DOI":"10.1128\/jvi.64.6.2725-2731.1990","volume":"64","author":"G Dubin","year":"1990","unstructured":"Dubin, G., Frank, I. & Friedman, H. M. Herpes simplex virus type 1 encodes two Fc receptors which have different binding characteristics for monomeric immunoglobulin G (IgG) and IgG complexes. J. Virol. 64, 2725\u20132731 (1990).","journal-title":"J. Virol."},{"key":"1295_CR146","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1128\/iai.21.2.442-447.1978","volume":"21","author":"R Adler","year":"1978","unstructured":"Adler, R., Glorioso, J. C., Cossman, J. & Levine, M. Possible role of Fc receptors on cells infected and transformed by herpesvirus: escape from immune cytolysis. Infect. Immun. 21, 442\u2013447 (1978).","journal-title":"Infect. Immun."},{"key":"1295_CR147","doi-asserted-by":"publisher","first-page":"4479","DOI":"10.1128\/jvi.63.11.4479-4488.1989","volume":"63","author":"I Frank","year":"1989","unstructured":"Frank, I. & Friedman, H. M. A novel function of the herpes simplex virus type 1 Fc receptor: participation in bipolar bridging of antiviral immunoglobulin G. J. Virol. 63, 4479\u20134488 (1989).","journal-title":"J. Virol."},{"key":"1295_CR148","first-page":"103","volume":"114","author":"HM Friedman","year":"2003","unstructured":"Friedman, H. M. Immune evasion by herpes simplex virus type 1, strategies for virus survival. Trans. Am. Clin. Climatol. Assoc. 114, 103\u2013112 (2003).","journal-title":"Trans. Am. Clin. Climatol. Assoc."},{"key":"1295_CR149","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.chom.2011.07.010","volume":"10","author":"K Manley","year":"2011","unstructured":"Manley, K. et al. Human cytomegalovirus escapes a naturally occurring neutralizing antibody by incorporating it into assembling virions. Cell Host Microbe 10, 197\u2013209 (2011).","journal-title":"Cell Host Microbe"},{"key":"1295_CR150","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.0040148","volume":"4","author":"ER Sprague","year":"2006","unstructured":"Sprague, E. R., Wang, C., Baker, D. & Bjorkman, P. J. Crystal structure of the HSV-1 Fc receptor bound to Fc reveals a mechanism for antibody bipolar bridging. PLoS Biol. 4, e148 (2006).","journal-title":"PLoS Biol."},{"key":"1295_CR151","doi-asserted-by":"publisher","first-page":"3262","DOI":"10.1128\/JVI.02855-15","volume":"90","author":"B Ndjamen","year":"2016","unstructured":"Ndjamen, B., Joshi, D. S., Fraser, S. E. & Bjorkman, P. J. Characterization of antibody bipolar bridging mediated by the human cytomegalovirus Fc receptor gp68. J. Virol. 90, 3262\u20133267 (2016).","journal-title":"J. Virol."},{"key":"1295_CR152","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S1386-6532(00)00084-6","volume":"17","author":"AD Brideau","year":"2000","unstructured":"Brideau, A. D., Enquist, L. W. & Tirabassi, R. S. The role of virion membrane protein endocytosis in the herpesvirus life cycle. J. Clin. Virol. 17, 69\u201382 (2000).","journal-title":"J. Clin. Virol."},{"key":"1295_CR153","doi-asserted-by":"publisher","first-page":"14184","DOI":"10.1074\/jbc.M313281200","volume":"279","author":"ER Sprague","year":"2004","unstructured":"Sprague, E. R., Martin, W. L. & Bjorkman, P. J. pH dependence and stoichiometry of binding to the Fc region of IgG by the herpes simplex virus Fc receptor gE\u2013gI. J. Biol. Chem. 279, 14184\u201314193 (2004).","journal-title":"J. Biol. Chem."},{"key":"1295_CR154","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003961","volume":"10","author":"B Ndjamen","year":"2014","unstructured":"Ndjamen, B., Farley, A. H., Lee, T., Fraser, S. E. & Bjorkman, P. J. The herpes virus Fc receptor gE\u2013gI mediates antibody bipolar bridging to clear viral antigens from the cell surface. PLoS Pathog. 10, e1003961 (2014).","journal-title":"PLoS Pathog."},{"key":"1295_CR155","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.immuni.2017.06.019","volume":"47","author":"HS Dai","year":"2017","unstructured":"Dai, H. S. et al. The Fc domain of immunoglobulin is sufficient to bridge NK cells with virally infected cells. Immunity 47, 159\u2013170.e10 (2017).","journal-title":"Immunity"},{"key":"1295_CR156","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1128\/jvi.56.2.489-494.1985","volume":"56","author":"PJ Johansson","year":"1985","unstructured":"Johansson, P. J., Myhre, E. B. & Blomberg, J. Specificity of Fc receptors induced by herpes simplex virus type 1: comparison of immunoglobulin G from different animal species. J. Virol. 56, 489\u2013494 (1985).","journal-title":"J. Virol."},{"key":"1295_CR157","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1002\/1521-4141(200009)30:9<2540::AID-IMMU2540>3.0.CO;2-S","volume":"30","author":"A Atherton","year":"2000","unstructured":"Atherton, A., Armour, K. L., Bell, S., Minson, A. C. & Clark, M. R. The herpes simplex virus type 1 Fc receptor discriminates between IgG1 allotypes. Eur. J. Immunol. 30, 2540\u20132547 (2000).","journal-title":"Eur. J. Immunol."},{"key":"1295_CR158","first-page":"631","volume":"83","author":"PJ Johansson","year":"1994","unstructured":"Johansson, P. J. et al. Studies of protein A and herpes simplex virus-1 induced Fc\u03b3-binding specificities. Different binding patterns for IgG3 from Caucasian and Oriental subjects. Immunology 83, 631\u2013638 (1994).","journal-title":"Immunology"},{"key":"1295_CR159","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1093\/infdis\/jis317","volume":"206","author":"JP Pandey","year":"2012","unstructured":"Pandey, J. P. Immunoglobulin genes and immunity to herpes simplex virus type 1. J. Infect. Dis. 206, 143\u2013144 (2012).","journal-title":"J. Infect. Dis."},{"key":"1295_CR160","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.4049\/jimmunol.1500872","volume":"195","author":"M Moraru","year":"2015","unstructured":"Moraru, M. et al. NK cell and Ig interplay in defense against herpes simplex virus type 1: epistatic interaction of CD16A and IgG1 allotypes of variable affinities modulates antibody-dependent cellular cytotoxicity and susceptibility to clinical reactivation. J. Immunol. 195, 1676\u20131684 (2015).","journal-title":"J. Immunol."},{"key":"1295_CR161","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s00281-014-0448-2","volume":"36","author":"E Corrales-Aguilar","year":"2014","unstructured":"Corrales-Aguilar, E., Hoffmann, K. & Hengel, H. CMV-encoded Fc\u03b3 receptors: modulators at the interface of innate and adaptive immunity. Semin. Immunopathol. 36, 627\u2013640 (2014).","journal-title":"Semin. Immunopathol."},{"key":"1295_CR162","doi-asserted-by":"publisher","first-page":"1106401","DOI":"10.3389\/fmicb.2022.1106401","volume":"13","author":"G Vezzani","year":"2022","unstructured":"Vezzani, G. et al. Human immunoglobulins are transported to HCMV viral envelope by viral Fc\u03b3 receptors-dependent and independent mechanisms. Front. Microbiol. 13, 1106401 (2022).","journal-title":"Front. Microbiol."},{"key":"1295_CR163","doi-asserted-by":"publisher","first-page":"3191","DOI":"10.1172\/JCI42955","volume":"120","author":"RJ Stanton","year":"2010","unstructured":"Stanton, R. J. et al. Reconstruction of the complete human cytomegalovirus genome in a BAC reveals RL13 to be a potent inhibitor of replication. J. Clin. Invest. 120, 3191\u20133208 (2010).","journal-title":"J. Clin. Invest."},{"key":"1295_CR164","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.63877","volume":"10","author":"P Kolb","year":"2021","unstructured":"Kolb, P. et al. Human cytomegalovirus antagonizes activation of Fc\u03b3 receptors by distinct and synergizing modes of IgG manipulation. eLife 10, e63877 (2021).","journal-title":"eLife"},{"key":"1295_CR165","doi-asserted-by":"publisher","first-page":"3490","DOI":"10.1128\/JVI.01476-07","volume":"82","author":"ER Sprague","year":"2008","unstructured":"Sprague, E. R. et al. The human cytomegalovirus Fc receptor gp68 Binds the Fc CH2\u2013CH3 interface of immunoglobulin G. J. Virol. 82, 3490\u20133499 (2008).","journal-title":"J. Virol."},{"key":"1295_CR166","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1038\/s44321-026-00372-1","volume":"18","author":"P Cramer","year":"2026","unstructured":"Cramer, P. et al. A viral glycoprotein targets IgG+ memory B cells to mediate humoral immune evasion. EMBO Mol. Med. 18, 795\u2013823 (2026).","journal-title":"EMBO Mol. Med."},{"key":"1295_CR167","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2425622122","volume":"122","author":"K Bentley","year":"2025","unstructured":"Bentley, K. et al. Virion proteomics of genetically intact HCMV reveals a regulator of envelope glycoprotein composition that protects against humoral immunity. Proc. Natl Acad. Sci. USA 122, e2425622122 (2025).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1295_CR168","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0050166","volume":"7","author":"M Cortese","year":"2012","unstructured":"Cortese, M. et al. Recombinant human cytomegalovirus (HCMV) RL13 binds human immunoglobulin G Fc. PLoS One 7, e50166 (2012).","journal-title":"PLoS One"},{"key":"1295_CR169","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1099\/vir.0.79888-0","volume":"85","author":"A Dolan","year":"2004","unstructured":"Dolan, A. et al. Genetic content of wild-type human cytomegalovirus. J. Gen. Virol. 85, 1301\u20131312 (2004).","journal-title":"J. Gen. Virol."},{"key":"1295_CR170","doi-asserted-by":"publisher","first-page":"7757","DOI":"10.1128\/jvi.68.12.7757-7765.1994","volume":"68","author":"R Th\u00e4le","year":"1994","unstructured":"Th\u00e4le, R., Lucin, P., Schneider, K., Eggers, M. & Koszinowski, U. H. Identification and expression of a murine cytomegalovirus early gene coding for an Fc receptor. J. Virol. 68, 7757\u20137765 (1994).","journal-title":"J. Virol."},{"key":"1295_CR171","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1128\/JVI.72.2.1377-1382.1998","volume":"72","author":"I Crnkovi\u0107-Mertens","year":"1998","unstructured":"Crnkovi\u0107-Mertens, I. et al. Virus attenuation after deletion of the cytomegalovirus Fc receptor gene is not due to antibody control. J. Virol. 72, 1377\u20131382 (1998).","journal-title":"J. Virol."},{"key":"1295_CR172","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1084\/jem.20060514","volume":"203","author":"T Lenac","year":"2006","unstructured":"Lenac, T. et al. The herpesviral Fc receptor fcr-1 down-regulates the NKG2D ligands MULT-1 and H60. J. Exp. Med. 203, 1843\u20131850 (2006).","journal-title":"J. Exp. Med."},{"key":"1295_CR173","doi-asserted-by":"publisher","first-page":"8422","DOI":"10.4049\/jimmunol.177.12.8422","volume":"177","author":"JD Mintern","year":"2006","unstructured":"Mintern, J. D. et al. Viral interference with B7-1 costimulation: a new role for murine cytomegalovirus fc receptor-1. J. Immunol. 177, 8422\u20138431 (2006).","journal-title":"J. Immunol."},{"key":"1295_CR174","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.molimm.2009.02.010","volume":"47","author":"J Arapovi\u0107","year":"2009","unstructured":"Arapovi\u0107, J., Lenac Rovis, T., Reddy, A. B., Krmpoti\u0107, A. & Jonji\u0107, S. Promiscuity of MCMV immunoevasin of NKG2D: m138\/fcr-1 down-modulates RAE-1epsilon in addition to MULT-1 and H60. Mol. Immunol. 47, 114\u2013122 (2009).","journal-title":"Mol. Immunol."},{"key":"1295_CR175","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-56419-3","volume":"16","author":"CE Otero","year":"2025","unstructured":"Otero, C. E. et al. Rhesus cytomegalovirus-encoded Fc\u03b3-binding glycoproteins facilitate viral evasion from IgG-mediated humoral immunity. Nat. Commun. 16, 1200 (2025).","journal-title":"Nat. Commun."},{"key":"1295_CR176","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36683-x","volume":"14","author":"AC Gomes","year":"2023","unstructured":"Gomes, A. C. et al. The cytomegalovirus gB\/MF59 vaccine candidate induces antibodies against an antigenic domain controlling cell-to-cell spread. Nat. Commun. 14, 1041 (2023).","journal-title":"Nat. Commun."},{"key":"1295_CR177","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1097\/00006454-199108000-00004","volume":"10","author":"AK Junker","year":"1991","unstructured":"Junker, A. K., Angus, E. & Thomas, E. E. Recurrent varicella-zoster virus infections in apparently immunocompetent children. Pediatric Infect. Dis. J. 10, 569\u2013575 (1991).","journal-title":"Pediatric Infect. Dis. J."},{"key":"1295_CR178","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.virol.2012.10.006","volume":"435","author":"AA Gershon","year":"2013","unstructured":"Gershon, A. A. Varicella zoster vaccines and their implications for development of HSV vaccines. Virology 435, 29\u201336 (2013).","journal-title":"Virology"},{"key":"1295_CR179","first-page":"17","volume":"123","author":"AA Gershon","year":"2012","unstructured":"Gershon, A. A. et al. Latency of varicella zoster virus in dorsal root, cranial, and enteric ganglia in vaccinated children. Trans. Am. Clin. Climatol. Assoc. 123, 17\u201333; discussion 33\u201335 (2012).","journal-title":"Trans. Am. Clin. Climatol. Assoc."},{"key":"1295_CR180","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1637\/21-00089","volume":"66","author":"T Kim","year":"2022","unstructured":"Kim, T. & Hearn, C. Vaccinal efficacy of recombinant Marek\u2019s disease vaccine 301B\/1 expressing chicken interleukin-15. Avian Dis. 66, 79\u201384 (2022).","journal-title":"Avian Dis."},{"key":"1295_CR181","doi-asserted-by":"publisher","first-page":"ofad500.2475","DOI":"10.1093\/ofid\/ofad500.2475","volume":"10","author":"L Panther","year":"2023","unstructured":"Panther, L. et al. Safety and immunogenicity of mRNA-1647, an mRNA-based cytomegalovirus vaccine in healthy adults: results of a phase 2, randomized, observer-blind, placebo-controlled, dose-finding trial. Open Forum Infect. Dis. 10, ofad500.2475\u00a0(2023).","journal-title":"Open Forum Infect. Dis."},{"key":"1295_CR182","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1016\/S1473-3099(23)00343-2","volume":"23","author":"R Das","year":"2023","unstructured":"Das, R. et al. Safety, efficacy, and immunogenicity of a replication-defective human cytomegalovirus vaccine, V160, in cytomegalovirus-seronegative women: a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Infect. Dis. 23, 1383\u20131394 (2023).","journal-title":"Lancet Infect. Dis."},{"key":"1295_CR183","doi-asserted-by":"publisher","first-page":"6273","DOI":"10.1073\/pnas.1800224115","volume":"115","author":"I Baraniak","year":"2018","unstructured":"Baraniak, I. et al. Protection from cytomegalovirus viremia following glycoprotein B vaccination is not dependent on neutralizing antibodies. Proc. Natl Acad. Sci. USA 115, 6273\u20136278 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1295_CR184","unstructured":"Lewis, A. L. et al. in Essentials of Glycobiology 4th edn Ch. 42 (eds Varki, A. et al.) (Cold Spring Harbor Laboratory Press, 2022)."},{"key":"1295_CR185","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-021-00409-1","volume":"6","author":"C Anish","year":"2021","unstructured":"Anish, C., Beurret, M. & Poolman, J. Combined effects of glycan chain length and linkage type on the immunogenicity of glycoconjugate vaccines. npj Vaccines 6, 150 (2021).","journal-title":"npj Vaccines"},{"key":"1295_CR186","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1038\/s41586-019-1250-z","volume":"570","author":"A Escolano","year":"2019","unstructured":"Escolano, A. et al. Immunization expands B cells specific to HIV-1 V3 glycan in mice and macaques. Nature 570, 468\u2013473 (2019).","journal-title":"Nature"},{"key":"1295_CR187","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/imr.12009","volume":"250","author":"ML Epperson","year":"2012","unstructured":"Epperson, M. L., Lee, C. A. & Fremont, D. H. Subversion of cytokine networks by virally encoded decoy receptors. Immunol. Rev. 250, 199\u2013215 (2012).","journal-title":"Immunol. Rev."},{"key":"1295_CR188","doi-asserted-by":"publisher","first-page":"13036","DOI":"10.1073\/pnas.1903317116","volume":"116","author":"JD Deere","year":"2019","unstructured":"Deere, J. D. et al. Neutralization of rhesus cytomegalovirus IL-10 reduces horizontal transmission and alters long-term immunity. Proc. Natl Acad. Sci. USA 116, 13036\u201313041 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1295_CR189","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/aje\/kwac170","volume":"192","author":"JC Nelson","year":"2023","unstructured":"Nelson, J. C. et al. Active postlicensure safety surveillance for recombinant zoster vaccine using electronic health record data. Am. J. Epidemiol. 192, 205\u2013216 (2023).","journal-title":"Am. J. Epidemiol."},{"key":"1295_CR190","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1080\/14760584.2017.1394843","volume":"16","author":"C Warren-Gash","year":"2017","unstructured":"Warren-Gash, C., Forbes, H. & Breuer, J. Varicella and herpes zoster vaccine development: lessons learned. Expert Rev. Vaccines 16, 1191\u20131201 (2017).","journal-title":"Expert Rev. Vaccines"},{"key":"1295_CR191","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/s41577-022-00821-1","volume":"23","author":"M Pyzik","year":"2023","unstructured":"Pyzik, M., Kozicky, L. K., Gandhi, A. K. & Blumberg, R. S. The therapeutic age of the neonatal Fc receptor. Nat. Rev. Immunol. 23, 415\u2013432 (2023).","journal-title":"Nat. Rev. Immunol."},{"key":"1295_CR192","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.jaci.2020.07.015","volume":"146","author":"DD Patel","year":"2020","unstructured":"Patel, D. D. & Bussel, J. B. Neonatal Fc receptor in human immunity: function and role in therapeutic intervention. J. Allergy Clin. Immunol. 146, 467\u2013478 (2020).","journal-title":"J. Allergy Clin. Immunol."},{"key":"1295_CR193","doi-asserted-by":"publisher","first-page":"5497","DOI":"10.4049\/jimmunol.1401218","volume":"194","author":"A Grevys","year":"2015","unstructured":"Grevys, A. et al. Fc engineering of human IgG1 for altered binding to the neonatal Fc receptor affects Fc effector functions. J. Immunol. 194, 5497\u20135508 (2015).","journal-title":"J. Immunol."},{"key":"1295_CR194","doi-asserted-by":"publisher","first-page":"eadu8579","DOI":"10.1126\/scitranslmed.adu8579","volume":"17","author":"MD Slein","year":"2025","unstructured":"Slein, M. D. et al. Eliminating interactions with the viral Fc receptor improves antibody-mediated protection against neonatal HSV infection in mice. Sci. Transl. Med. 17, eadu8579 (2025).","journal-title":"Sci. Transl. Med."},{"key":"1295_CR195","first-page":"223","volume":"438","author":"MJ Levin","year":"2023","unstructured":"Levin, M. J. & Weinberg, A. Immune responses to varicella-zoster virus vaccines. Curr. Top. Microbiol. Immunol. 438, 223\u2013246 (2023).","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"1295_CR196","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/rmv.535","volume":"17","author":"A Kenneson","year":"2007","unstructured":"Kenneson, A. & Cannon, M. J. Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Rev. Med. Virol. 17, 253\u2013276 (2007).","journal-title":"Rev. Med. Virol."},{"key":"1295_CR197","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.20736","volume":"4","author":"P Ssentongo","year":"2021","unstructured":"Ssentongo, P. et al. Congenital cytomegalovirus infection burden and epidemiologic risk factors in countries with universal screening: a systematic review and meta-analysis. JAMA Netw. Open\u00a04, e2120736 (2021).","journal-title":"JAMA Netw. Open"},{"key":"1295_CR198","unstructured":"Liu, F. & Zhou, Z. H. in Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis Ch. 3 (eds Arvin, A. et al.) (Cambridge Univ. Press, 2007)."},{"key":"1295_CR199","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1093\/infdis\/151.3.464","volume":"151","author":"RR McKendall","year":"1985","unstructured":"McKendall, R. R. IgG-mediated viral clearance in experimental infection with herpes simplex virus type 1: role for neutralization and Fc-dependent functions but not C\u2032 cytolysis and C5 chemotaxis. J. Infect. Dis. 151, 464\u2013470 (1985).","journal-title":"J. Infect. Dis."},{"key":"1295_CR200","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1128\/iai.37.3.1132-1137.1982","volume":"37","author":"N Balachandran","year":"1982","unstructured":"Balachandran, N., Bacchetti, S. & Rawls, W. E. Protection against lethal challenge of BALB\/c mice by passive transfer of monoclonal antibodies to five glycoproteins of herpes simplex virus type 2. Infect. Immun. 37, 1132\u20131137 (1982).","journal-title":"Infect. Immun."},{"key":"1295_CR201","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/j.micinf.2008.08.001","volume":"10","author":"K Ishibashi","year":"2008","unstructured":"Ishibashi, K. et al. Strain-specific seroepidemiology and reinfection of cytomegalovirus. Microbes Infect. 10, 1363\u20131369 (2008).","journal-title":"Microbes Infect."},{"key":"1295_CR202","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1093\/infdis\/158.6.1220","volume":"158","author":"ML Landry","year":"1988","unstructured":"Landry, M. L. & Zibello, T. A. Ability of herpes simplex virus (HSV) types 1 and 2 to induce clinical disease and establish latency following previous genital infection with the heterologous HSV type. J. Infect. Dis. 158, 1220\u20131226 (1988).","journal-title":"J. Infect. Dis."},{"key":"1295_CR203","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1099\/jmm.0.027771-0","volume":"60","author":"AL Schoenfisch","year":"2011","unstructured":"Schoenfisch, A. L. et al. Cytomegalovirus (CMV) shedding is highly correlated with markers of immunosuppression in CMV-seropositive women. J. Med. Microbiol. 60, 768\u2013774 (2011).","journal-title":"J. Med. Microbiol."},{"key":"1295_CR204","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-014-0568-2","volume":"14","author":"JD Stowell","year":"2014","unstructured":"Stowell, J. D. et al. Cross-sectional study of cytomegalovirus shedding and immunological markers among seropositive children and their mothers. BMC Infect. Dis. 14, 568 (2014).","journal-title":"BMC Infect. Dis."},{"key":"1295_CR205","doi-asserted-by":"publisher","DOI":"10.1111\/tid.13977","volume":"24","author":"CN Kotton","year":"2022","unstructured":"Kotton, C. N. et al. Cytomegalovirus in the transplant setting: where are we now and what happens next? A report from the International CMV Symposium 2021. Transpl. Infect. Dis. 24, e13977 (2022).","journal-title":"Transpl. Infect. Dis."},{"key":"1295_CR206","doi-asserted-by":"publisher","first-page":"104211","DOI":"10.1016\/j.jcv.2019.104211","volume":"123","author":"PA Grossi","year":"2020","unstructured":"Grossi, P. A., Baldanti, F., Andreoni, M. & Perno, C. F. CMV infection management in transplant patients in Italy. J. Clin. Virol. 123, 104211 (2020).","journal-title":"J. Clin. Virol."},{"key":"1295_CR207","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ebiom.2019.11.005","volume":"50","author":"I Baraniak","year":"2019","unstructured":"Baraniak, I. et al. Seronegative patients vaccinated with cytomegalovirus gB-MF59 vaccine have evidence of neutralising antibody responses against gB early post-transplantation. EBioMedicine 50, 45\u201354 (2019).","journal-title":"EBioMedicine"},{"key":"1295_CR208","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1093\/infdis\/jiy102","volume":"217","author":"I Baraniak","year":"2018","unstructured":"Baraniak, I. et al. Epitope-specific humoral responses to human cytomegalovirus glycoprotein-B vaccine with MF59: anti-AD2 levels correlate with protection from viremia. J. Infect. Dis. 217, 1907\u20131917 (2018).","journal-title":"J. Infect. Dis."},{"key":"1295_CR209","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.3390\/v16081294","volume":"16","author":"N Law","year":"2024","unstructured":"Law, N., Logan, C. & Taplitz, R. EBV reactivation and disease in allogeneic hematopoietic stem cell transplant (HSCT) recipients and its impact on HSCT outcomes. Viruses 16, 1294\u00a0(2024).","journal-title":"Viruses"},{"key":"1295_CR210","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.bbmt.2006.09.003","volume":"13","author":"A Yamane","year":"2007","unstructured":"Yamane, A. et al. Risk factors for developing human herpesvirus 6 (HHV-6) reactivation after allogeneic hematopoietic stem cell transplantation and its association with central nervous system disorders. Biol. Blood Marrow Transpl. 13, 100\u2013106 (2007).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"1295_CR211","doi-asserted-by":"publisher","first-page":"174.e1","DOI":"10.1016\/j.jtct.2020.10.011","volume":"27","author":"H Nakayama","year":"2021","unstructured":"Nakayama, H. et al. Impact of specific antibody level on human herpesvirus 6 reactivation after allogeneic stem cell transplantation. Transplant. Cell. Ther. 27, 174.e1\u2013174.e5 (2021).","journal-title":"Transplant. Cell. Ther."},{"key":"1295_CR212","doi-asserted-by":"publisher","first-page":"14389","DOI":"10.3390\/ijms232214389","volume":"23","author":"O Shechter","year":"2022","unstructured":"Shechter, O., Sausen, D. G., Gallo, E. S., Dahari, H. & Borenstein, R. Epstein\u2013Barr virus (EBV) epithelial associated malignancies: exploring pathologies and current treatments. Int. J. Mol. Sci. 23, 14389 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"1295_CR213","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.canlet.2009.07.004","volume":"289","author":"KW Wen","year":"2010","unstructured":"Wen, K. W. & Damania, B. Kaposi sarcoma-associated herpesvirus (KSHV): molecular biology and oncogenesis. Cancer Lett. 289, 140\u2013150 (2010).","journal-title":"Cancer Lett."},{"key":"1295_CR214","first-page":"505","volume":"9","author":"DN Posnett","year":"2008","unstructured":"Posnett, D. N. Herpesviruses and autoimmunity. Curr. Opin. Investig. Drugs 9, 505\u2013514 (2008).","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"1295_CR215","doi-asserted-by":"publisher","first-page":"362","DOI":"10.3390\/microorganisms12020362","volume":"12","author":"L Sokolovska","year":"2024","unstructured":"Sokolovska, L., Cistjakovs, M., Matroze, A., Murovska, M. & Sultanova, A. From viral infection to autoimmune reaction: exploring the link between human herpesvirus 6 and autoimmune diseases. Microorganisms 12, 362 (2024).","journal-title":"Microorganisms"},{"key":"1295_CR216","doi-asserted-by":"publisher","first-page":"eabc1726","DOI":"10.1126\/sciadv.abc1726","volume":"6","author":"B Vollmer","year":"2020","unstructured":"Vollmer, B. et al. The prefusion structure of herpes simplex virus glycoprotein B. Sci. Adv. 6, eabc1726 (2020).","journal-title":"Sci. Adv."}],"container-title":["Nature Reviews Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41579-026-01295-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41579-026-01295-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41579-026-01295-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T14:03:42Z","timestamp":1781877822000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41579-026-01295-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":216,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1295"],"URL":"https:\/\/doi.org\/10.1038\/s41579-026-01295-x","relation":{},"ISSN":["1740-1526","1740-1534"],"issn-type":[{"value":"1740-1526","type":"print"},{"value":"1740-1534","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,13]]},"assertion":[{"value":"19 February 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.R.P. has served as a consultant to Moderna, Pfizer, Dynavax, Kamada, Imunon and Merck, and has led sponsored programmes with Moderna, Pfizer, Dynavax and Kamada. M.E.A. has a sponsored project with Moderna and patents\/applications related to antibody-based interventions against neonatal herpes simplex virus (nHSV) infection. P.K. serves as a consultant to Oak Hill Bio and had a sponsored project with Biotest AG (2022\u20132024). These activities had no impact on this article. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}